Abstract
To investigate the relationship between human leukocyte antigen (HLA) class I and II alleles and treatment-induced anemia in chronic hepatitis C (CHC) patients receiving combination therapy with pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV). One hundred six naïve CHC patients (59 females and 47 males; mean age, 53.08 years) who underwent combination treatment were enrolled. The patients were considered positive for hemoglobin (Hb)-related side effects if the Hb concentrations dropped below 10 g/dl during PEG-IFN-α plus RBV treatment. The HLA-A, -B, -C, -DR, and -DQ loci were investigated by sequence-based genotyping. The effects of the clinical characteristics, virologic variables, and the HLA alleles on treatment-induced anemia were evaluated by a logistic regression analysis. Forty patients (37.7%) had Hb levels below 10 g/dl during the treatment course. Low baseline Hb levels and an advanced liver fibrosis stage were associated with decreases in Hb levels to below 10 g/dl. The occurrence of treatment-related anemia (Hb < 10 g/dl) was significantly associated with HLA-B*15:02 as shown by multivariate analysis (adjusted odds ratio, 8.13; 95% confidence interval: 1.19-55.70; P-value after Holm's procedure, 0.03). HLA-B*15:02 is associated with treatment-induced anemia in Taiwanese CHC patients receiving combination therapy with PEG-IFN-α plus RBV.
© 2012 John Wiley & Sons A/S.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Anemia / chemically induced
-
Anemia / genetics*
-
Anemia / immunology
-
Anemia / virology
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / adverse effects*
-
Drug Therapy, Combination / adverse effects
-
Female
-
Genotype
-
HLA-B15 Antigen / genetics*
-
HLA-B15 Antigen / immunology
-
Hemoglobins / analysis
-
Hepacivirus / drug effects
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / complications
-
Hepatitis C, Chronic / genetics*
-
Hepatitis C, Chronic / immunology
-
Hepatitis C, Chronic / virology
-
Histocompatibility Antigens Class I / genetics
-
Histocompatibility Antigens Class I / immunology
-
Histocompatibility Antigens Class II / genetics
-
Histocompatibility Antigens Class II / immunology
-
Histocompatibility Testing
-
Humans
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / adverse effects*
-
Liver Cirrhosis / etiology
-
Liver Cirrhosis / genetics*
-
Liver Cirrhosis / immunology
-
Liver Cirrhosis / virology
-
Male
-
Middle Aged
-
Polyethylene Glycols / administration & dosage
-
Polyethylene Glycols / adverse effects*
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Ribavirin / administration & dosage
-
Ribavirin / adverse effects*
-
Sequence Analysis, DNA
Substances
-
Antiviral Agents
-
HLA-B*15:02 antigen
-
HLA-B15 Antigen
-
Hemoglobins
-
Histocompatibility Antigens Class I
-
Histocompatibility Antigens Class II
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2a